Deactivation of the lipopolysaccharide antagonist eritoran (E5564) by high-density lipoprotein-associated apolipoproteins

Innate Immunity

Volumn 18, Issue 1, 2012, Pages 171-178

  Fleischer, Jacklyn G ^a   Rossignol, Dan ^b   Francis, Gordon A ^a   Chan, Teddy ^a   Lynn, Melvyn ^b   Wasan, Kishor M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b EISAI INC   (United States)

Author keywords

Apo A1; E5564; endotoxin; eritoran; HDL; LPS

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; ERITORAN; HIGH DENSITY LIPOPROTEIN; LIPOPOLYSACCHARIDE; SERUM AMYLOID A;

ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG ACTIVITY; DRUG INACTIVATION; ENZYME INACTIVATION; HUMAN; NONHUMAN; PROTEIN FUNCTION; SEPSIS; STIMULATION;

APOLIPOPROTEIN A-I; APOLIPOPROTEIN A-II; BINDING, COMPETITIVE; BLOOD CELLS; DISACCHARIDES; HUMANS; LIPID A; LIPOPROTEINS, HDL; MOLECULAR STRUCTURE; SERUM AMYLOID A PROTEIN; SUGAR PHOSPHATES; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84856002353     PISSN: 17534259     EISSN: 17534267     Source Type: Journal    
DOI: 10.1177/1753425910394395     Document Type: Article

References (29)

1. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992 ; 101: 1644-1644
2. Dombrovskiy VY, Martin AA, Sunderram J, Paz HL. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med. 2007 ; 35: 1244-1244
3. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Cri Care Med. 2001 ; 29: 1303-1303
4. Hawkins LD, Christ WJ, Rossignol DP. Inhibition of endotoxin response by synthetic TLR4 antagonists. Curr Top Med Chem. 2004 ; 4: 1147-1171 (Pubitemid 38923439)
5. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 1998 ; 282: 2085-2085
6. Lynn M, Rossignol DP, Wheeler JL, Kao RJ, Perdomo CA, Noveck R, et al. Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia. J Infect Dis. 2003 ; 187: 631-631
7. Mullarkey M, Rose JR, Bristol J, Kawata T, Kimura A, Kobayashi S, et al. Inhibition of endotoxin response by E5564, a novel toll-like receptor 4-directed endotoxin antagonist. J Pharmacol Exp Ther. 2003 ; 304: 1093-1102 (Pubitemid 36254422)
8. Wong YN, Rossignol D, Rose JR, Kao R, Carter A, Lynn M. Safety, pharmacokinetics, and pharmacodynamics of E5564, a lipid A antagonist, during an ascending single-dose clinical study. J Clin Pharmacol. 2003 ; 43: 735-742 (Pubitemid 36759151)
9. Jonas , Ana , Michael C Phillips Biochemistry of Lipids, Lipoproteins and Membranes. 5 th edn. Amsterdam: Elsevier, 2008, pp. 485-506. Vance DE Vance JE, ed. Amsterdam: Elsevier ; 2008: 485-506.
10. Wasan KM, Sivak O, Cote RA, MacInnes AI, Boulanger KD, Lynn M, et al. Association of the endotoxin antagonist E5564 with high-density lipoproteins in vitro: dependence on low-density and triglyceride-rich lipoprotein concentrations. Antimicrob Agents Chemother. 2003 ; 47: 2796-2803 (Pubitemid 37040250)
11. Rossignol DP, Wasan KM, Choo E, Yau E, Wong N, Rose J, et al. Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healthy volunteers. Antimicrob Agents Chemother. 2004 ; 48: 3233-3240 (Pubitemid 39129312)
12. Levine DM, Parker TS, Donnelly TM, Walsh A, Rubin AL. In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci USA. 1993 ; 90: 12040-12044 (Pubitemid 24008776)
13. Berbee JF, van der Hoogt CC, de Haas CJ, van Kessel KP, Dallinga-Thie GM, Romijn JA, et al. Plasma apolipoprotein CI correlates with increased survival in patients with severe sepsis. Intensive Care Med. 2008 ; 34: 907-911 (Pubitemid 351571192)
14. Marsche G, Frank S, Raynes JG, Kozarsky KF, Sattler W, Malle E. The lipidation status of acute-phase protein serum amyloid A determines cholesterol mobilization via scavenger receptor class B, type I. Biochem J. 2007 ; 402: 117-117
15. Van Oosten M, Rensen PC, Van Amersfoort ES, Van Eck M, Van Dam AM, Breve JJ, et al. Apolipoprotein E protects against bacterial lipopolysaccharide- induced lethality. A new therapeutic approach to treat gram-negative sepsis. J Biol Chem. 2001 ; 276: 8820-8824
16. Berbee JF, van der Hoogt CC, Kleemann R, Schippers EF, Kitchens RL, van Dissel JT, et al. Apolipoprotein CI stimulates the response to lipopolysaccharide and reduces mortality in gram-negative sepsis. FASEB J. 2006 ; 20: 2162-2164
17. Rensen PC, Oosten M, Bilt E, Eck M, Kuiper J, Berkel TJ. Human recombinant apolipoprotein E redirects lipopolysaccharide from Kupffer cells to liver parenchymal cells in rats in vivo. J Clin Invest. 1997 ; 99: 2438-2445 (Pubitemid 27227722)
18. Flegel WA, Baumstark MW, Weinstock C, Berg A, Northoff H. Prevention of endotoxin-induced monokine release by human low- and high-density lipoproteins and by apolipoprotein A-I. Infect Immun. 1993 ; 61: 5140-5146 (Pubitemid 23353891)
19. Wang Y, Zhu X, Wu G, Shen L, Chen B. Effect of lipid-bound apoA-I cysteine mutants on lipopolysaccharide-induced endotoxemia in mice. J Lipid Res. 2008 ; 49: 1640-1640
20. Imai T, Fujita T, Yamazaki Y. Beneficial effects of apolipoprotein A-I on endotoxemia. Surg Today. 2003 ; 33: 684-687 (Pubitemid 37072217)
21. Wang WQ, Merriam DL, Moses AS, Francis GA. Enhanced cholesterol efflux by tyrosyl radical-oxidized high density lipoprotein is mediated by apolipoprotein AI-AII heterodimers. J Biol Chem. 1998 ; 273: 17391-17398 (Pubitemid 28355066)
22. Wang WQ, Moses AS, Francis GA. Cholesterol mobilization by free and lipid-bound apoAI(Milano) and apoAI(Milano)-apoAII heterodimers. Biochemistry. 2001 ; 40: 3666-3673 (Pubitemid 32242824)
23. Rose JR, Mullarkey MA, Christ WJ, Hawkins LD, Lynn M, Kishi Y, et al. Consequences of interaction of a lipophilic endotoxin antagonist with plasma lipoproteins. Antimicrob Agents Chemother. 2000 ; 44: 504-510 (Pubitemid 30117933)
24. Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science. 1985 ; 229: 869-869
25. Cabana VG, Feng N, Reardon CA, Lukens J, Webb NR, de Beer FC, et al. Influence of apoA-I and apoE on the formation of serum amyloid A-containing lipoproteins in vivo and in vitro. J Lipid Res. 2004 ; 45: 317-317
26. Havel RJ, Kane JP The Online Metabolic and Molecular Basis of Inherited Disease. Valle D Beaudet AL Vogelstein B Kinzler KW Antonarakis SE Ballabio A, ed. New York: The McGraw-Hill Companies, Inc ; 2001: 1-7.
27. Luo CC, Li WH, Moore MN, Chan L. Structure and evolution of the apolipoprotein multigene family. J Mol Biol. 1986 ; 187: 325-340 (Pubitemid 16083775)
28. Segrest JP, De Loof H, Dohlman JG, Brouillette CG, Anantharamaiah GM. Amphipathic helix motif: classes and properties. Proteins. 1990 ; 8: 103-117 (Pubitemid 20262536)
29. Wasan KM, Brocks DR, Lee SD, Sachs-Barrable K, Thornton SJ. Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery. Nat Rev Drug Discov. 2008 ; 7: 84-99